Home Blog

Red Light Holland’s Radix Motion 3D Movement Data and AI Innovations Patent Application Granted Entry to “Patent Prosecution Highway” (PPH) and Accorded “Special” Status

0

Toronto, Ontario–(Newsfile Corp. – June 1, 2023) – Radix Motion, a fully-owned technology subsidiary of Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light Holland” or the “Company”), an Ontario-based corporation engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws, is pleased to announce that further to its press release dated January 31, 2023, its U.S. “continuation-in-part” (CIP) application has been granted the right to participate in the “Patent Prosecution Highway” program and accorded “special” status.

The Patent Prosecution Highway (PPH) is a fast-track examination procedure that allows applicants to reach final disposition of a patent application more quickly and efficiently than standard examination processing. As applications examined under the PPH program have a higher likelihood of allowance, it is hoped this decision will swiftly lead to an issued patent in the U.S., and subsequently in other PPH jurisdictions where a PPH request is also granted.

Radix Motion’s claims are directed to the use of human movement data in psychedelic-assisted therapy, including as a tool to promote positive experiences, to prevent negative experiences, to predict and personalize individual patient experiences, and to evaluate the efficacy of the therapy.

The patent application also covers Radix Motion’s technology on the use of real-time analysis of human movement data to identify the position and body movement of a psychedelic facilitator or therapist to detect if a potential violation is occurring and activate real time alerts and safety measures. This technology does not require sending or storing any video information and helps to protect patient privacy.

With this new technology, Radix Motion is leading the way in creating safer and more private psychedelic therapy sessions for clients.

“There is a huge opportunity to improve trust, safety and privacy both for clients and facilitators in psychedelic sessions with this technology which we believe will ultimately lead to better efficacy,” said Sarah Hashkes, CEO of Radix Motion and CTIO or Red Light Holland. “Human movement data in combination with AI is also an untapped gold mine for clinical research and new psychedelic compound development.”

“Getting accepted into the Patent Prosecution Highway program is a great boost toward receiving a timely and cost effective patent,” said Graham Pechenik, a registered patent attorney and the founder of Calyx Law, and Red Light Holland’s senior advisor. “We appreciate the opportunity to protect Radix Motion’s inventions, in ways that are aligned with its goal of ethical IP and its core value of protecting user’s privacy”.

“We’re proud that our embodied technology can help establish responsible best practices around psychedelics and contribute to positive change in the emerging psychedelic ecosystem. This patent application is an important milestone for us, and we believe that the potential licensing or sale of this technology could provide another revenue stream for Red Light Holland. We appreciate the expertise of patent lawyer Graham Pechenik and the Calyx Law team in protecting our investment, particularly under the Patent Prosecution Highway program,” said Todd Shapiro, CEO and Director of Red Light Holland.

About Radix Motion

Radix Motion is a technology company founded in Silicon Valley focused on building immersive and embodied technology for health and wellness. Amongst their products are Meu, an AR/VR interactive hologram messenger, iMicroapp a microdosing app that also measures poses, Wisdom VR, an interactive education that explains what psychedelics do to the brain and more.

About Red Light Holland

Red Light Holland is an Ontario-based corporation engaged in the production, growth and sale of functional mushrooms and mushroom home grow kits in North America and Europe, and a premium brand of psilocybin truffles to the legal, recreational market within the Netherlands, in compliance with all applicable laws.

For additional information, please contact:

Todd Shapiro
Chief Executive Officer and Director
Tel: 647-643-TRIP (8747)
Email: [email protected]
Website: www.RedLight.co

Forward-Looking Information and Cautionary Statements

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events.

The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding: the Company’s performance, business objectives and milestones and the anticipated timing of, and costs in connection with, the execution or achievement of such objectives and milestones; the Company’s intention to devote resources to the protection of its intellectual property rights, including the use of the PPH procedure; the Company and Radix Motion’s continued eligibility to participate in the fast-track examination offered by the Patent Prosecution Highway in the U.S., Canada, and other participating patent offices; the potential benefits of the PPH program, including the improvement of trust, safety, and privacy for clients and facilitators, the likelihood of allowance, cost effectiveness and expediency of the PPH program, and the PPH’s alignment with Radix Motion’s goal of ethical IP and its core value of protecting user’s privacy; the potential benefits of psychedelic usage data, including clinical research and psychedelic compound development; Radix Motion’s technology will help it lead the way by being an invaluable asset in creating safer and more private psychedelic therapy sessions for clients; the Company’s technology can help establish responsible best practices around psychedelics and contribute to positive change in the emerging psychedelic ecosystem; the patent application being an important milestone for the Company, and its belief that the potential licensing or sale of its technology could provide another revenue stream the Company.

Forward-looking information in this press release are based on certain assumptions and expected future events, namely: the Company’s ability to maintain or achieve its performance, business objectives and milestones and the anticipated timing of, and costs in connection with, the execution or achievement of such objectives and milestones; the Company’s ability to devote resources to the protection of its intellectual property rights, including the use of the PPH procedure; the Company and Radix Motion’s ability to maintain their continued eligibility to participate in the fast-track examination offered by the Patent Prosecution Highway in the U.S., Canada, and other participating patent offices; the continued availability and the Company’s realisation of the potential benefits of the PPH program, including the the improvement of trust, safety, and privacy for clients and facilitators, the likelihood of allowance, cost effectiveness and expediency of the PPH program, and the PPH’s alignment with Radix Motion’s goal of ethical IP and its core value of protecting user’s privacy; the Company’s realisation of the potential benefits of psychedelic usage data, including clinical research and psychedelic compound development; Radix Motion’s ability to realise on its technology will help it lead the way by being an invaluable asset in creating safer and more private psychedelic therapy sessions for clients; the Company ability to use its technology to help establish responsible best practices around psychedelics and contribute to positive change in the emerging psychedelic ecosystem; the patent application will be an important milestone for the Company; and that the potential licensing or sale of its technology will provide another revenue stream the Company.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to:the Company’s inability to maintain or achieve its performance, business objectives and milestones and the anticipated timing of, and costs in connection with, the execution or achievement of such objectives and milestones; the Company’s inability to devote resources to the protection of its intellectual property rights, including the use of the PPH procedure; the Company and Radix Motion’s inability to maintain their continued eligibility to participate in the fast-track examination offered by the Patent Prosecution Highway in the U.S., Canada, and other participating patent offices; the lack of availability and the Company’s inability to realise the potential benefits of the PPH program, including the the improvement of trust, safety, and privacy for clients and facilitators, the likelihood of allowance, cost effectiveness and expediency of the PPH program, and the PPH’s alignment with Radix Motion’s goal of ethical IP and its core value of protecting user’s privacy; the Company’s inability to realise the potential benefits of psychedelic usage data, including clinical research and psychedelic compound development; Radix Motion’s inability to realise on its technology will help it lead the way by being an invaluable asset in creating safer and more private psychedelic therapy sessions for clients; the Company’s inability to use its technology to help establish responsible best practices around psychedelics and contribute to positive change in the emerging psychedelic ecosystem; the patent application will not be an important milestone for the Company; and that the potential licensing or sale of its technology will not provide another revenue stream the Company.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/168340

Bloom Montana is Thrilled to Announce Whitefish’s Grand Opening

0

Whitefish Montana–(Newsfile Corp. – June 1, 2023) – Bloom Montana, a leading local cannabis company, is excited to announce the grand opening of their latest Bloom marijuana dispensary in Whitefish. This marks the 24th dispensary opened by the esteemed company, solidifying their commitment to providing top-quality cannabis products to the community.

Located at 333 Baker Ave, Whitefish, MT 59937, the Bloom Montana Dispensary Whitefish location caters to both medical and recreational consumers. Offering a wide range of products and daily deals. The dispensary will operate Monday through Sunday, from 9 AM to 8 PM, accommodating various schedules and offering convenience to the local community.

Whitefish, known for its scenic beauty and outdoor recreational activities, offers an ideal setting for the new Bloom Montana dispensary. With the famous Whitefish ski resort nearby, winter enthusiasts can conveniently access quality cannabis products for their ski adventure. Moreover, during the summer months, visitors can enjoy mountain biking in the area, taking advantage of the dispensary’s convenient location.

Additionally, the dispensary’s proximity to the breathtaking Glacier National Park, a mere 20-30 minutes away, further enhances the appeal of the new location. Customers can conveniently stock up on their cannabis essentials before embarking on their memorable adventures in the park.

“This new space allows us to enhance the overall experience for our valued customers, providing a welcoming environment where they can explore and discover their preferred cannabis products. We look forward to serving the Whitefish community and being a trusted source of top-quality cannabis.” – says Adam Kunin of Bloom Montana.

Featured Brand: The Clear

The Clear, a national cannabis brand headquartered in Colorado, currently partners with Bloom Montana dispensaries. Bloom assists with the manufacturing of all of the products made locally in Montana. The brand prides itself on being one of the first to introduce molecular distillation to the market and effectively revolutionized the industry.

The Clear has garnered the trust and loyalty of numerous customers and they recently earned five trophies at Rooster Magazines’ THC Classic cannabis competition, including the #1 Flavored Vape and #1 New Product awards in 2023.

For more information about Bloom Montana and its range of products, please visit their website at www.bloommt.com.

About: Bloom Montana is dedicated to becoming the most trusted cannabis provider in Montana. They pride themselves on being locally owned, grown, and tested, ensuring the highest standards of quality and accountability. Bloom’s primary goal is to offer premium cannabis to every resident of Montana.

CONTACT: Adam Kunin
PHONE: 314-368-1105
EMAIL: [email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/168222

Aleafia Health Announces Extension of Forbearance Under Loan Agreement With Senior Lender

0

TORONTO, June 01, 2023 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, OTCQB: ALEAF) (“Aleafia Health” or the “Company”) announces that the Company has entered into a forbearance agreement with NE SPC II LP (“NE SPC”) extending the forbearance period under its loan agreement with NE SPC until June 5, 2023. The forbearance agreement comes in light of ongoing negotiations between the Company, NE SPC and a potential alternative lender regarding a potential refinancing of the indebtedness existing under the Company’s loan agreement with NE SPC dated December 24, 2021 and as previously amended by agreements dated March 28, 2022, June 17, 2022, and May 15, 2023 (the “Loan Agreement”). 

As previously disclosed by the Company, NE SPC recently agreed to amend the terms of the Loan Agreement and to forbear from enforcing its rights under the Loan Agreement until the earlier of (a) an event of default, or (b) May 31, 2023.

No decisions relating to any potential refinancing have been made as at the date of this news release and the Company does not intend to comment further with respect to a potential refinancing, or any other transaction which may result from the strategic review process announced by the Company on May 25, 2023, unless and until it determines that additional disclosure is appropriate in the circumstances and in accordance with applicable securities laws.

For Investor & Media Relations

Matthew Sale, CFO
[email protected]
LEARN MORE: www.AleafiaHealth.com

About Aleafia Health:

The Company is a federally licensed Canadian cannabis company offering cannabis products in Canadian adult-use and medical markets and in select international markets, including Australia and Germany. The Company operates a virtual medical cannabis clinic staffed by physicians and nurse practitioners which provide health and wellness services across Canada.

The Company owns three licensed cannabis production facilities and operates a strategically located distribution centre all in the province of Ontario, including the largest, outdoor cannabis cultivation facility in Canada. The Company produces a diverse portfolio of cannabis and cannabis derivative products including dried flower, pre-roll, milled, vapes, oils, capsules, edibles, sublingual strips and topicals.

Cautionary Note Regarding Forward-Looking Statements

Certain statements herein relating to the Company constitute “forward-looking information” within the meaning of applicable securities laws. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things, statements regarding: the ability of the Company, NE SPC and the potential alternative lender to successfully negotiate a potential refinancing, the potential results and timing of the Company’s strategic review process, and the potential structure and timing of one or more potential transactions which may result from that process. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of the Company to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in the Company’s filings, available on the SEDAR website at www.sedar.com. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, the Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change.

SJS/TEN Treatment Market to Observe Highest Growth of USD 12,586.71 Million with an Excellent CAGR of 7.6% by 2030

0

HOUSTON, May 31, 2023 (GLOBE NEWSWIRE) — The newest report from Data Bridge Market Research, “SJS/TEN Treatment Market” examines growth strategies, drivers, opportunities, key segments, Porter’s Five Forces analysis, and the competitive environment in detail. SJS/TEN Treatment market research document help business or organization in every sphere of trade to take better decisions, to respond the toughest business questions, and reduce the risk of failure. It gives details about market drivers and market restraints which can help businesses in guessing about reducing or increasing the production of a particular product. A strong research methodology used here consists of data models that include a market overview and guide, vendor positioning grid, market timeline analysis, company positioning grid, company market share analysis, standards of measurement, top to bottom analysis, and vendor share analysis. Market share analysis and key trend analysis are the two other major success factors in SJS/TEN Treatment market report.

The leading SJS/TEN Treatment business report provides the supreme base for competitor analysis, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market and SJS/TEN Treatment industry. This is a professional and meticulous report, which focuses on primary and secondary drivers, market share, leading segments, and geographical analysis. The report also helps to know about the types of consumers, their response and views about particular products, and their thoughts on the step-up of a product. The most appropriate method for the distribution of certain products can also be analyzed with SJS/TEN Treatment market research study.

The global SJS/TEN treatment market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 7.6% in the forecast period of 2023 to 2030 and is expected to reach USD 12,586.71 million by 2030 from USD 7,100.00 million in 2022.

Get a Sample PDF of the SJS/TEN Treatment Market @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-sjs-ten-treatment-market

The treatment market for Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) is relatively small due to the rarity of these diseases.   

The SJS/TEN treatment market is dominated by drugs, as drugs are the main form of treatment for these conditions. Corticosteroids, intravenous immunoglobulin (IVIG), and antibiotics are the most commonly used medications in the treatment of SJS/TEN.

The global SJS/TEN treatment market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue-impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for safe distribution of machine and drug products are the major drivers which propelled the demand of the market in the forecast period.

The Latest Study Conducts a Comprehensive Analysis of the Global Market, considering the current competitive landscape and its future evolution in the next few years.

The global SJS/TEN Treatment market is experiencing rapid growth, fueled by rising demands, industrialization, consumer awareness, and technological advancements. Sales and revenue in this sector have surged at an exponential pace, and the market’s expansion is expected to continue over the projected period.

In order to expand their market share and reach a wider client base, leading businesses in the worldwide SJS/TEN Treatment market are heavily investing in research and development. The study provides detailed insights into the strategies, financial health, revenue, gross margin, and growth rates of these companies.

Opportunity:

  • Developing Effective and Safe Treatment for SJS/TEN

Stem cell transplantation is a new approach that aims to replace damaged skin and mucous membranes with healthy tissue. Autologous stem cell transplantation, where stem cells are taken from the patient’s skin and grown in culture before being transplanted back into the damaged area, has shown promising results in small studies.

Recent Developments:

  • In June 2020, BD, a leading global medical technology company announced that they have completed the acquisition of Straub Medical AG, a privately-held company. With this acquisition, the company has added the valuable expertise and experience of Straub Medical AG and expanded its product portfolio. This will help the company to expand and grow in the market.
  • In January 2019, Mölnlycke Health Care AB. acquires MandJ Airlaid Products A/S to further strengthen its wound care capabilities. In connection with the acquisition, MandJ, and its employees will be an integral part of Mölnlycke. The acquisition will improve Mölnlycke’s security of supply for the air-laid material needed to produce advanced wound dressings and help grow the wound care business by accelerating innovation and product development in existing and future products. This will help the company to expand and grow in the market.

The most prominent players in the SJS/TEN Treatment market include.

  • Cardinal Health (U.S.)
  • Smith + Nephew (U.K.)
  • Novartis AG (Switzerland)
  • Amneal Pharmaceuticals LLC. (U.S.)
  • Amgen Inc. (U.S.)
  • Pfizer Inc. (U.S.)
  • Colgate-Palmolive Company (U.S.)
  • Merck & Co., Inc. (U.S.)
  • Mölnlycke Health Care AB. (Sweden)
  • Xttrium Laboratories (U.S.)
  • Schülke & Mayr GmbH (Germany)
  • ICPA Health Products Ltd (India)
  • Purdue Pharma L.P. (U.S.)
  • Eugia (Subsidiary of Aurobindo Pharma)
  • AdvaCare PharmaTop of Form

Click Here to Download the Complete Research Study in PDF Format @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-sjs-ten-treatment-market
Our market intelligence platform provides a range of benefits that will help you gain valuable insights and stay ahead in the market. By utilizing our platform, you can:

  • Identify emerging market trends and dynamics
  • Access high-quality and accurate market intelligence
  • Benchmark your performance against competitors and industry standards
  • Explore competitive strategies and analyze market share
  • Discover regional market opportunities that may have been overlooked
  • Choose from multiple deliverable formats, including PDF, PPT, Excel, and an online dashboard

With our comprehensive market intelligence platform, you can easily access the information you need to make informed decisions and stay ahead of the competition.

At Data Bridge Market Research, we employ a comprehensive and iterative research methodology aimed at minimizing deviations to provide the most accurate estimates and forecasts possible. Our approach involves utilizing both bottom-up and top-down methods to segment and estimate the quantitative aspects of the market. Furthermore, a recurring theme across all our research reports is data triangulation, which examines the market from three distinct perspectives.

To derive our market estimates and forecasts, we employ simulation models that are tailored for each study. We gather information on market dynamics, technology landscape, application development, and pricing trends, which are then fed into the model and analyzed simultaneously. We compare these factors and quantify their impact on the forecast period using correlation, regression, and time series analysis. Our market forecasting is performed using a combination of economic tools, technological analysis, and our team’s industry experience and domain expertise.

Key Market Segments Covered in SJS/TEN Treatment Industry Research

Treatment

  • Medications
  • Support Care
  • Hospitalization

Diagnosis

  • Physical Exam
  • Medical History
  • Skin Biopsy

Cause

  • Specific Treatment

Route of Administration

  • Parenteral

Drug Type

Therapy Type

  • Monotherapy
  • Combination Therapy

Patient Type

End User

  • Specialty Clinics
  • Ambulatory Surgical Center
  • Homecare Setting

Distribution Channel

  • Direct Tenders
  • Retail Pharmacies

Explore Further Details about This Research Report @ https://www.databridgemarketresearch.com/reports/global-sjs-ten-treatment-market

Key Industry Drivers:

  • Increasing Prevalence and Incidence of SJS/TEN

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are serious and potentially life-threatening conditions involving the skin and mucous membranes. SJS and TEN are considered two ends of the disease spectrum, with SJS being the milder form and TEN being the more severe form. A characteristic feature of these conditions is the separation of the epidermis (the outer layer of the skin) from the dermis (the layer below the skin) due to a strong immune reaction.

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but serious skin diseases characterized by the separation of the epidermis from the dermis. The incidence of SJS/TEN has been reported to be around 1 per million people per year. However, in recent years there has been increased concern about the incidence and prevalence of SJS/TEN. 

  • Advances in Drug Development for SJS/TEN Treatment

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are serious and potentially life-threatening conditions that require prompt and aggressive treatment. Although there is currently no specific medication or treatment that can cure SJS/TEN, advances in drug development have led to better treatment strategies and treatment outcomes for affected patients. But there are various clinical trials going on for drug development for SJS/TEN treatment.

SJS/TEN Treatment Market Regional Analysis/Insights:

The countries covered in this SJS/TEN Treatment Market Report U.S., Canada, Mexico, Germany, U.K., France, Italy, Russia, Spain, Netherlands, Denmark, Switzerland, Sweden, Poland, Norway, Finland, Belgium, Turkey, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Indonesia, Philippines, Thailand,  Malaysia, Singapore, Vietnam, Taiwan, Rest of Asia-Pacific, Saudi Arabia,  South Africa, Bahrain, Kuwait, Oman, Qatar, U.A.E., Egypt, Israel, and Rest of Middle East and Africa, Brazil, Argentina, Rest of South America.

Asia-Pacific is expected to dominate the global SJS/TEN treatment market. China dominates in the Asia-Pacific region due to the presence of key market players in the largest consumer market with high GDP.

Core Objective of SJS/TEN Treatment Market:

Every firm in the SJS/TEN Treatment market has objectives but this market research report focus on the crucial objectives, so you can analyze about competition, future market, new products, and informative data that can raise your sales volume exponentially.

  • SJS/TEN Treatment Market Size and growth rate factors.
  • Important changes in the future SJS/TEN Treatment Market.
  • Top worldwide competitors of the Market.
  • Scope and product outlook of SJS/TEN Treatment Market.
  • Developing regions with potential growth in the future.
  • Tough Challenges and risk faced in the Market.
  • Global SJS/TEN Treatment top manufacturers profile and sales statistics

Table of Contents:

  1. Introduction
  2. Market Segmentation
  3. Executive Summary
  4. Premium Insights
  5. Global SJS/TEN Treatment Market: Regulations
  6. Market Overview
  7. Global SJS/TEN Treatment Market, By Treatment
  8. Global SJS/TEN Treatment Market, By Diagnosis
  9. Global SJS/TEN Treatment Market, By Cause
  10. Global SJS/TEN Treatment Market, By Route of Administration
  11. Global SJS/TEN Treatment Market, By Drug Type
  12. Global SJS/TEN Treatment Market, By Therapy Type
  13. Global SJS/TEN Treatment Market, By Patient Type
  14. Global SJS/TEN Treatment Market, By End User
  15. Global SJS/TEN Treatment Market, By Distribution Channel
  16. Global SJS/TEN Treatment Market, By Region
  17. Global SJS/TEN Treatment Market: Company Landscape
  18. SWOT Analyses
  19. Company Profile
  20. Questionnaires
  21. Related Reports

Download the Complete Table of Contents @ https://www.databridgemarketresearch.com/toc/?dbmr=global-sjs-ten-treatment-market

Explore More Reports:

  • Europe SJS/TEN Treatment Market, By Treatment (Medications, Support care, Hospitalization, Isolation, Ointments and Others), Diagnosis (Physical Exam, Skin Biopsy, Medical History, Blood Test, Cultures and Others), Cause (Specific Treatment, Infection and Others), Route of Administration (Oral, Parenteral, Topical and Others), Drug Type (Branded and Generic), Therapy Area (Combination Therapy and Monotherapy), Patient Type (Geriatric, Adult and Pediatric), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Center, Homecare Setting and Others), Distribution Channel (Retail Pharmacies, Direct Tender and Others) – Industry Trends and Forecast to 2030 https://www.databridgemarketresearch.com/reports/europe-sjs-ten-treatment-market
  • Asia-Pacific SJS/TEN Treatment Market, By Treatment (Medications, Support care, Hospitalization, Isolation, Ointments and Others), Diagnosis (Physical Exam, Skin Biopsy, Medical History, Blood Test, Cultures and Others), Cause (Specific Treatment, Infection and Others), Route of Administration (Oral, Parenteral, Topical and Others), Drug Type (Branded and Generic), Therapy Area (Combination Therapy and Monotherapy), Patient Type (Geriatric, Adult and Pediatric), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Center, Homecare Setting and Others), Distribution Channel (Retail Pharmacies, Direct Tender and Others) – Industry Trends and Forecast to 2030 https://www.databridgemarketresearch.com/reports/asia-pacific-sjs-ten-treatment-market
  • Middle East and Africa SJS/TEN Treatment Market, By Treatment (Medications, Support care, Hospitalization, Isolation, Ointments and Others), Diagnosis (Physical Exam, Skin Biopsy, Medical History, Blood Test, Cultures and Others), Cause (Specific Treatment, Infection and Others), Route of Administration (Oral, Parenteral, Topical and Others), Drug Type (Branded and Generic), Therapy Area (Combination Therapy and Monotherapy), Patient Type (Geriatric, Adult and Pediatric), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Center, Homecare Setting and Others),     Distribution Channel (Retail Pharmacies, Direct Tender and Others) – Industry Trends and Forecast to 2030 https://www.databridgemarketresearch.com/reports/middle-east-and-africa-sjs-ten-treatment-market
  • North America SJS/TEN Treatment Market, By Treatment (Medications, Support care, Hospitalization, Isolation, Ointments and Others), Diagnosis (Physical Exam, Skin Biopsy, Medical History, Blood Test, Cultures and Others), Cause (Specific Treatment, Infection and Others), Route of Administration (Oral, Parenteral, Topical and Others), Drug Type (Branded and Generic), Therapy Area (Combination Therapy and Monotherapy), Patient Type (Geriatric, Adult and Pediatric), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Center, Homecare Setting and Others), Distribution Channel (Retail Pharmacies, Direct Tender and Others) – Industry Trends and Forecast to 2030 https://www.databridgemarketresearch.com/reports/north-america-sjs-ten-treatment-market

About Data Bridge Market Research:

An absolute way to forecast what the future holds is to comprehend the trend today!

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- [email protected]

Beverage Brand Incubator and Accelerator Harmony Craft Beverages Launches First Field and Trade Marketing Program Specifically for Cannabis Drinks

0

The B2B Portfolio Program Taps Cannabis Experts and Beverage Industry Specialists

Los Angeles, California–(Newsfile Corp. – May 31, 2023) – Harmony Craft Beverages (“HCB”), a portfolio company of Sands Lane Ventures that serves as beverage brand incubator and accelerator for low- and no-alcohol and functional infused drinks, today announces the launch of the first field and trade marketing program specifically created for cannabis infused beverages. The program will be led by a team of experts in both the traditional beverage and cannabis industries, offering a strategic perspective and approach designed to drive product awareness, increase category education, and drive sales both in retail and direct to consumer channels.

Building on its success as an incubator in helping develop and launch cannabis beverages such as Herbacée botanical wines, Klaus ready-to-drink craft cocktails and Malus infused ciders, HCB’s new portfolio program offers cannabis beverage brands support services that include a variety of at-retail and co-marketing opportunities, such as beverage specialized activations and pop-ups. The program leverages tried-and-true trade and consumer marketing models used in the wine and spirits industry while fine-tuning and adapting the approach specifically for cannabis beverages and the nuances that come along with the nascent sector.

“The cannabis beverage category is one of the fastest growing, yet distributors and retailers are still struggling to serve this segment for various reasons,” said Evan Eneman, co-founder and interim CEO of HCB. “We believe that by creating beverage-first programming, activations and strategies, we can help brands move the needle at retail and engage with both the trade and consumers in entirely new ways. We built the Harmony Craft Beverages Field and Trade Marketing Program to offer cost effective and value added targeted services and support that cannabis beverage brands need to help engage consumers and grow their business.”

HCB has been leading beverage activations at cannabis industry events for the last two years including during Hall of Flowers, MJUnpacked, MJBizCon and others, and recently hosted pop-ups at local farmers’ markets where attendees were able to taste non-infused samples and make DTC orders on-site, a New York City Summer Speakeasy event, an art gallery opening and more, with future opportunities and unique, engaging activations to come.

HCB’s team of advisors and experts include Debbie Novograd, an advisor to non-alcoholic beverage brands, former Starbucks international marketing executive, and most recently the former CEO of low- and no-alcohol innovator BevZero, who will advise on brand and marketing strategy through the program alongside other industry experts including former Head of Innovation at Vertosa Austin Stevenson and brewer and formulator Chris Anderson.

“It has been a delight and honor to work with Evan over the past several years-both as a client and colleague-as Harmony Craft Beverages has grown and expanded to offer the array of services it does today,” said Novograd, advisor of HCB. “The entire HCB team are some of the most creative, dedicated, passionate and overall talented group of individuals I have worked with throughout my 30-plus years in food and beverages. From market research and development to sales, distribution and overall marketing, HCB has the expertise and experience to help low- and no-alcohol and infused functional beverage brands of all sizes achieve their goals.”

To learn more about the Field and Trade Marketing Portfolio Program and other brand services offered, please visit harmonycraftbeverages.com and contact [email protected] for more information.

ABOUT HARMONY CRAFT BEVERAGES

Harmony Craft Beverages (HCB) is a beverage brand incubator and accelerator building the innovation pipeline and paving the path for brand growth and infrastructure development in low- and no-alcohol and functional infused-beverages. HCB helps develop premium beverage brands and products using state-of-the-art technology and processes by utilizing a full-service suite of innovative solutions including brand development and design, product development, formulation, distribution, sales and marketing, finance and accounting. Our unique ecosystem of resources and team of cannabis, hospitality, and food and beverage experts strategically provide beverage-first services and resources that help brands succeed as part of its Portfolio model. For more information, visit HarmonyCraftBeverages.com and follow along on Instagram and LinkedIn.

##

Media Contact
Harmony Craft Beverages
Juliet Fairbrother
[email protected]

Company Contact
Harmony Craft Beverages
Evan Eneman
[email protected]

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/168158

Cartel Blue, Inc. Announces Nano-Enhanced THC Product

0

Laguna Niguel, California–(Newsfile Corp. – May 31, 2023) – Cartel Blue, Inc. (OTC Pink: CRTL), a Nevada corporation, and manufacturer of THC products, edible gummies, vape pens, CBD oil, hemp cigars and branded accessories announced the addition of a new enhanced version of its CBD hydration product – Nano Oil Water Soluble CBD Hydration. The new formulation of this product contains 0.3 THC, psychoactive compound delta-9-tetrahydrocannabinol, which has been enhanced by nanotechnology produced by UCLA’s NanoLab in Los Angeles, California, vastly improving its effectiveness.

Cartel Blue’s CEO, Philip Moreb advised, nano enhanced THC is a game changer, making the Nano Oil Water Soluble CBD Hydration product more effective in its delivery of accurate potency and strength. Mr. Moreb explained that when Cartel Blue’s new nano enhanced product is compared to other THC products currently available in today’s market, most competitive products fail to deliver potency and strength because traditional formulations of THC in liquid form break off or form flakes. This causes the cannabinoids in the THC to disperse, resulting in the product, falling well below the desired 0.3 THC delivery threshold. Cartel Blue’s nano enhanced product does not disperse, thereby maintaining its potency and strength, delivering 0.3 THC as verified by third-party certified laboratories.

Cartel Blue’s Nano Oil Water Soluble CBD Hydration product is available as a tincture which can be used topically or taken orally, and is available for purchase by consumers https://cartelscigars.com/

THC has been the center of recent research studies, showing efficacy in multiple therapeutic areas including cancer, and has been shown in clinical studies to have inhibiting properties. Nano technology enhancement enables the targeted delivery of biologic and natural compounds such as THC https://nanolab.ucla.edu/ https://cnsi.ucla.edu/research-initiatives/nanomedicines-for-cancer/

About Cartel Blue, Inc.

Cartel Blue, Inc. manufactures and distributes hemp consumable products, including 0.3 THC (psychoactive compound delta-9-tetrahydrocannabinol) edible gummies, CBD oil products, vape pens, branded cigars and cigarillos, and accessories, and their common stock currently trades on the OTC Exchange OTC Market’s Pinks under the symbol “CRTL”.

Safe Harbor Disclaimer

This press release may contain certain forward-looking statements and information, as defined within the meaning of the Private Securities Litigation Reform Act of 1995, or Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the safe harbor created by those sections, as applicable. Such forward-looking statements include, the development, costs, and results of new business opportunities and uses words such as “plan(s)”, “intend(s)”, “anticipate(s),” “seek”, “believe”, “estimate,” “expect”, “project”, or similar phrases to summarize beliefs, plans, expectations, or intentions regarding the future, and are forward-looking in nature and subject to risks, uncertainties, and other factors, which may cause the actual results, performance, or achievements of Cartel Blue, Inc. to be materially different from the statements made herein. Actual results could differ from those projected in any forward-looking statements.

For Additional Information, please contact:

Cartel Blue, Inc.
Investor Relations (310) 955-0099
Email: [email protected]
Website: www.cartelscigars.com

Source: Cartel Blue, Inc.

Cannot view this image? Visit: https://i0.wp.com/grassnews.net/wp-content/uploads/2023/05/cartel-blue-inc-announces-nano-enhanced-thc-product.jpg?w=696&ssl=1

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8148/168152_ebc286fa2465c970_002full.jpg

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/168152

BioHarvest Reports Q1 2023 Results Demonstrating Strong Year Over Year Growth

0

  • VINIA® revenues grew 209% compared to Q1 2022 to reach USD 2.2 M
  • Reiterating guidance for year-on-year revenue growth of 3 X to reach USD 17M+
  • Gross margins continue to improve towards target required to achieve projected cash flow break even in Q4 2023.
  • Reduction in marketing expenses as percentage of revenue demonstrating improved sales efficiency

Vancouver, British Columbia and Rehovot, Israel–(Newsfile Corp. – May 31, 2023) – BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) (FSE: 8MV) (“BioHarvest” or “the Company”) announces that it has released Q1 2023 results. Revenue of its flagship VINIA® product reached USD 2.2M, representing 209% growth compared to the same quarter of last year. Net loss for the quarter was USD 752K (includes USD 1.9M nonrecurring amount)*, compared to USD 2.13M in Q1 2022. The Company is reiterating both its announced revenue guidance of USD 17M+ for the year, and that it is targeting to be cash flow “break-even” by Q4 of this year. The Company has already successfully completed a large proportion of its required fundraising activities and is forecasting that the current financing round will fund all operations until the Company reaches the target of financial independence by year end.

BioHarvest has focused for the first half of this year on the improvement in production yield and driving a reduction in the cost of goods despite major supply chain inflationary cost pressures. Gross margins in Q1 2023 increased to 37%, from 26% in Q1 2022, representing an improvement of 42%. The Company is focused on the continued improvement of gross profit margins with increased manufacturing scale, on the introduction of new drying technologies to optimize yield levels, and on implementing additional cost reduction measures.

The increase in the number of new customers driven by the health benefits that VINIA® delivers is an assurance of the ability of the business to grow further and achieve the scale required for profitability. VINIA® sales metrics continue to improve and increased marketing efficiency has been achieved in Q1. Cost of customer acquisition in Q1 2023 declined by 13% compared to Q1 2022, further demonstrating the power of the VINIA® brand. VINIA® continues to achieve a best-in-class verified customer rating of 4.7 out of 5 with over 2,200 verified reviews, demonstrating its significant positive impact to consumers’ lives.

The company plans to introduce new products such as VINIA® Functional Coffee by year end which will not only fuel revenue growth but would also further increase production and marketing efficiency.

“I am proud of our Q1 results”, stated CEO Ilan Sobel, adding “We made some tough decisions in Q1 which aimed at building a healthy and profitable business. I strongly believe that the renewed focus resulting from these decisions is paying off and is yielding the desired results both in growth and ultimately in near term profitability. Our activities across all departments are flexing our biotech muscles and are demonstrating the power of our technology platform. I look forward to the upcoming months, where our shareholder partners will see the continued demonstration of this progress.”

The Company will hold a LIVE Shareholder presentation on June 22nd at 2pm Eastern Time. The interactive meeting will include a discussion of the 1st quarter results, an update on marketing and new product activities, and a Q+A session with Dr Brian Cornblatt. All interested media and investors are welcome to register here: https://us02web.zoom.us/webinar/register/WN_48UxbdppR5GfBHwGnKyCgg

*Note: The USD 1.9M reduction in the net loss reported for Q1 is due to a fair value adjustment of derivative liability related to a convertible loan. This accounting line item had zero impact on cash flow.

About BioHarvest Sciences

BioHarvest Sciences Inc. (CSE: BHSC) is a fast-growing Biotech firm listed on the Canadian Securities Exchange. BioHarvest has developed a patented bio-cell growth platform technology capable of growing the active and beneficial ingredients in fruit and plants, at an industrial scale, without the need to grow the plant itself. BioHarvest is currently focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinically proven therapeutic solutions, within two major business verticals – nutraceutical health and wellness products such as dietary supplements, and development of plant cell-based Active Pharmaceutical Ingredients (API’s) that focus on specific medical indications.

BioHarvest Sciences Inc.
Ilan Sobel, Chief Executive Officer

For further information, please contact:
Dave Ryan, VP Investor Relations & Director
Phone: 1 (604) 622 -1186
Email: [email protected]

Forward-Looking Statements

Information set forth in this news release might include forward-looking statements that are based on management’s current estimates, beliefs, intentions, and expectations, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Launching new products is subject to risks and uncertainties including the risk that the market will not accept the product or that government approvals required for sale or import of the products will not be obtained. There is no assurance that the Company will reach break-even cash flow by Q4 2023, as that is dependent on a combination of factors such as supply chain efficiencies, input cost stability, marketing efficiencies and uncertain consumer preferences.

All forward-looking statements are inherently uncertain and actual results may be affected by a number of material factors beyond our control. Readers should not place undue reliance on forward-looking statements. BHSC does not intend to update forward-looking statement disclosures other than through our regular management discussion and analysis disclosures.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accept responsibility for the adequacy or accuracy of this release.

 

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/168157

Historic Milestone: UK Patients Receive First CannEpil® Delivery through ‘I AM Billy Foundation’ and GMC Specialist Register

0

 

MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a leading European pharmaceutical firm specializing in plant-derived medications, announced today that its ground-breaking Investigational Medicinal Product (IMP), CannEpil®, has been successfully imported and received by its first patients in the United Kingdom.

CannEpil® is a high-CBD, low-THC formulation, delivered via an oral mucosal solution. It is part of MGC’s rigorous clinical development programme for patients suffering from refractory epilepsy, also known as drug-resistant epilepsy. Following a safety study in Australia, which confirmed CannEpil® was safe for post-treatment driving activities, CannEpil® was distributed and prescribed in Ireland under full governmental health insurance coverage in 2019.

The first patient to receive CannEpil® in the UK was supported by the ‘I AM Billy Foundation’, an initiative led by Charlotte Caldwell, whose son Billy was the first person to receive an NHS prescription for medical cannabis in 2018. Approximately 25,000 people in the UK are currently treated with medical cannabis for conditions such as chronic pain, epilepsy, and Parkinson’s disease.

Besides, MGC Pharma has delivered CannEpil® to its first patient in the UK via the Named Patient Request programme, following the announcement on 11th April 2023. The initiative permits clinicians listed on The General Medical Council (GMC) specialist register to prescribe CannEpil®.

The delivery also supports the RESCAS study, a research initiative aiming to address the substantial unmet medical need of refractory epilepsy. MGC Pharma’s proprietary ZAM app, announced on 15th March 2023, will record patients’ daily metrics, symptoms, and treatment impact, providing a detailed record of the study and a deeper understanding of CannEpil® effects on refractory epilepsy patients.

CannEpil® was supplied to the ‘I AM Billy Foundation’ through the NHS’s Refractory Epilepsy Specialist Clinical Advisory Service, the only route in the UK for patients to receive public funding for cannabis-based treatments of refractory epilepsy.

Roby Zomer, Managing Director and CEO of MGC Pharma, said: “Fulfilling the first UK patient’s CannEpil® treatment signifies MGC Pharma’s commitment to improving access to effective epilepsy treatment. We’re proud to collaborate with the ‘I AM Billy Foundation’ on this significant endeavor. We aim to ensure patient access to high-quality, cannabis-based medicinal products. With the first CannEpil® prescription via Named Patient Request, we’re making substantial progress towards increasing access to effective refractory epilepsy treatment in the UK and Ireland, with other key territories to soon follow.”

High Tide Applauds Repeal of 6% Fee on Manitoba Cannabis Sales

0

 

High Tide Inc. (“High Tide” or the “Company“) (Nasdaq: HITI) (TSXV: HITI) (FSE: 2LYA), Canada’s largest non-franchised retail cannabis chain which owns 10 Canna Cabana stores in Manitoba, welcomes yesterday’s passage of Bill 10 by the Manitoba legislature which will result in the repeal of Manitoba’s 6% Social Responsibility Fee on legal cannabis sales retroactive to January 1st, 2022. This will return approximately $181 million in fees paid by legal cannabis retailers over the past two years while ensuring that at least an additional $11 million2 stays with retailers moving forward on an annualized basis.

“We welcome the fact that the Manitoba legislature has voted to put $18 million back into the cannabis industry retroactively while ensuring at least $11 million stays in the hands of legal retailers, who offer tested and regulated products on an annual basis. This will help Manitoba’s legal cannabis retailers of all sizes maintain margins while re-investing in their businesses so they can better compete with a well-entrenched illicit market, and I want to thank both the PC and NDP MLAs for their support to pass this legislation,” said Raj Grover, President and Chief Executive Officer of High Tide.

“While today’s announcement is a positive first step, much more needs to be done, especially by the federal government, to ensure the sustainability of Canada’s legal cannabis sector, which directly employs tens of thousands of Canadians but is struggling to succeed under the current regulatory and legislative environment. We encourage other provinces and the federal government to follow Manitoba’s lead and come up with concrete measures to ensure our industry continues to grow and create jobs while protecting public health,” added Mr. Grover.

CBD Beverages Market to Witness Strong Growth with a CAGR of 28.7% and Reach a Value of US$ 46221.8 Million by 2032

0

 

CBD Beverages are alcoholic and non-alcoholic that are infused with cannabidiol (CBD). CBD Beverages are available in various flavors and can be enjoyed hot or cold. CBD Beverages also helps in relieving joint pain, help in regulating digestion and are widely marketed as over the products as food supplements. CBD products are offered as safe alternative and free of recreational, CBD use in Germany is high with approx. half of population, 4.3% of population has used them, and 1.1% are current users.

Growing demand for functional beverages has become major factor in market growth. Wide variety of benefits of CBD such as help in reducing anxiety, manage pain, aches, help in relaxing and also assist with sleep has given rise in demand for CBD beverage market growth in coming years.

Order free Sample Copy of the Report:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/5041

(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, Table of Contents, Graphical introduction of regional analysis, Top players in the market with their revenue analysis and our research methodology.)

Our Sample Report Includes:

  • 2032 Updated Report Introduction, Overview, and In-depth industry analysis.
  • 115+ Pages Research Report (Inclusion of Updated Research).
  • Provide Chapter-wise guidance on Request.
  • 2023 Updated Regional Analysis with Graphical Representation of Size, Share & Trends.
  • Includes Updated List of table & figures.

Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis.

Market Dynamics:

The CBD beverages market is a dynamic and rapidly evolving industry. Several key market dynamics are shaping its growth and development:

  • Increasing Consumer Demand: Consumer interest in CBD-infused products, including beverages, has been on the rise. Consumers are seeking natural alternatives for wellness and relaxation, and CBD beverages offer a convenient and enjoyable way to incorporate CBD into their daily routines.
  • Wellness and Functional Beverage Trends: The growing focus on health and wellness has driven the demand for functional beverages. CBD beverages align with this trend, as they offer potential therapeutic benefits such as stress relief, relaxation, and sleep support. Consumers are actively seeking out beverages that offer both hydration and additional functional properties.
  • Regulatory Landscape: The regulatory environment surrounding CBD beverages varies by country and region. In some areas, CBD is classified as a dietary supplement, while in others, it may fall under specific food and beverage regulations. The evolving regulations and guidelines influence product formulation, labeling, and marketing practices in the CBD beverage market.

Overall, the market dynamics of CBD beverages are driven by consumer demand, regulatory factors, product innovation, and competition. As the industry continues to evolve, companies that adapt to changing market dynamics and prioritize quality, transparency, and consumer education are likely to succeed in this burgeoning market.

Key Highlights:

  • In May 2023, Naka launched new all-natural CBD water drink as an alternative to alcoholic drinks. New launched “Naka Moonlight” drink contains 30mg equivalent CBD per can which help in reducing alcohol consumption and also help in relaxation.
  • In November 2022, Ablis launched new potency of its CBD beverages and shooters in all drinks with doubling CBD isolates in each beverage. Ablis created CBD drink with all natural ingredients and high quality products and made from 100% pure hemp CBD isolate.

Growth Drivers:

Several key factors are driving the growth of the CBD beverages market:

  • Increasing Consumer Awareness: As consumer awareness about the potential benefits of CBD increases, there is a growing interest in CBD-infused beverages. Consumers are seeking natural alternatives for wellness and are attracted to the potential therapeutic effects of CBD, such as relaxation, stress relief, and sleep support.
  • Health and Wellness Trends: The health and wellness movement has been a significant driver of CBD beverage growth. Consumers are actively looking for functional and healthier beverage options. CBD beverages align with this trend as they offer the potential for additional benefits beyond hydration, such as natural ingredients and potential relaxation properties.
  • Expanding Legalization and Regulation: The legalization and regulation of CBD products in many countries and regions have provided a favorable environment for the growth of the CBD beverages market. As regulations become clearer and more standardized, it becomes easier for companies to develop and market CBD-infused beverages, thereby expanding the market’s reach.

These growth drivers collectively contribute to the increasing demand and market expansion of CBD beverages. However, it’s important to note that market dynamics can vary based on regional regulations, consumer preferences, and other factors.

Growth Restrains:

While the CBD beverages market is experiencing growth, there are several factors that can act as restraints or challenges to its expansion:

  • Regulatory Uncertainty: The regulatory landscape surrounding CBD is still evolving and can vary significantly across different countries and regions. Unclear regulations or restrictions on CBD-infused products, including beverages, can create barriers to market growth. Companies may face challenges in navigating complex regulatory requirements and ensuring compliance, which can limit product availability and consumer access.
  • Lack of Standardization: The CBD industry lacks standardized regulations and quality control measures. Inconsistent CBD quality, varying extraction methods, and inaccurate labeling can undermine consumer trust and hinder market growth. Without clear standards, it can be difficult for consumers to make informed choices, leading to uncertainty and potential reluctance to try CBD beverages.
  • Limited Scientific Research: While there is growing interest and anecdotal evidence about the potential benefits of CBD, there is still a need for more scientific research to support these claims. The limited availability of robust clinical studies and regulatory restrictions on making health claims can slow down market growth. Lack of scientific evidence may result in consumer skepticism and reluctance to embrace CBD-infused beverages.

It’s important to address these growth restraints through proactive industry collaboration, investment in research and development, adherence to regulatory compliance, consumer education initiatives, and transparency in product quality and labeling. Overcoming these challenges will be crucial for the sustained growth and expansion of the CBD beverages market.

Request Free Pdf copy of the report:

https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/5041

Analyst View:

Presence of major key players and new product launch has become major contribution in market growth. As CBD Beverage is a functional beverage its demand is rising due to health awareness, rising demand for sport drinks, energy drinks, which makes feel relax and calm. Rising demand for beer, spirits among consumers is expected to provide lucrative opportunities in CBD Beverage market growth over the forecast period.

Opportunities:

The CBD beverages market presents several opportunities for growth and development:

  • Expanding Legalization: As more countries and regions legalize the production and sale of CBD products, it creates opportunities for market expansion. New markets opening up provide opportunities for companies to enter and establish their presence, leading to increased product availability and consumer access.
  • Increasing Consumer Acceptance: Consumer acceptance of CBD-infused products, including beverages, is growing. As CBD becomes more mainstream and perceptions shift towards its potential health benefits, there is an opportunity to capture a broader consumer base. Educating consumers about CBD, addressing misconceptions, and highlighting the potential benefits can further drive adoption and market growth.
  • Rising Demand for Functional Beverages: The demand for functional and wellness beverages continues to grow. CBD beverages align with this trend by offering potential relaxation, stress relief, and other therapeutic benefits. There is an opportunity to tap into the growing consumer interest in functional beverages and position CBD beverages as a natural and alternative option.

By capitalizing on these opportunities, companies in the CBD beverages market can position themselves for growth, attract new consumers, and establish a strong foothold in the evolving industry.

Challenges:

The CBD beverages market faces several challenges that can impact its growth and development:

  • Regulatory Complexity: The regulatory landscape surrounding CBD products, including beverages, can be complex and vary from country to country. Compliance with evolving regulations, such as labeling requirements, THC limits, and licensing processes, can be challenging for companies operating in multiple jurisdictions. Navigating these regulations and ensuring compliance adds complexity and cost to the business operations.
  • Lack of Clear Regulations: In some regions, there is a lack of clear regulations specifically tailored to CBD beverages. This ambiguity can create uncertainty for manufacturers and retailers, hindering market growth. The absence of standardized regulations on CBD dosage, quality control, and manufacturing practices can lead to inconsistencies in product offerings and consumer trust.
  • Quality Control and Standardization: The CBD industry lacks standardized quality control measures and product testing protocols. Ensuring consistent CBD potency, purity, and safety across different batches and brands can be a challenge. Without established quality standards, there is a risk of inconsistent product quality, which can undermine consumer confidence and trust in CBD beverages.

Navigating these challenges requires proactive industry collaboration, investment in research and development, adherence to regulatory compliance, consumer education initiatives, and quality control measures. Overcoming these obstacles will be crucial for the sustained growth and success of the CBD beverages market.

Customization Available:

https://www.prophecymarketinsights.com/market_insight/Insight/request-customization/5041

You can also check out some of the Top-Selling Related Research Reports:

  • Cannabidiol (CBD) Market accounted for US$ 2.9 billion in 2020 and is estimated to be US$ 17.39 billion by 2030 and is anticipated to register a CAGR of 19.8%.
  • Medical Cannabis Market accounted for US$ 6,822.21 million in 2020 and is estimated to be US$ 45587.48 million by 2030 and is anticipated to register a CAGR of 23.5%.
  • CBD-Infused Beverages Market accounted for US$ 260.5 Million in 2020 and is estimated to be US$ 2082.9 Million by 2029 and is anticipated to register a CAGR of 26.0%.